Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination.
DNA vaccines can induce both humoral and cellular immune responses. Although some DNA vaccines are already licensed for infectious diseases in animals, they are not licensed for human use because the risk and benefit of DNA vaccines is still controversial. Indeed, in humans, the immunogenicity of DNA vaccines is lower than that of other traditional vaccines. To develop the use of DNA vaccines in the clinic, various approaches are in progress to enhance or improve the immunogenicity of DNA vaccines. Recent studies have shown that immunogenicity of DNA vaccines are regulated by innate immune responses via plasmid DNA recognition through the STING-TBK1 signaling cascade. Similarly, molecules that act as dsDNA sensors that activate innate immune responses through STING-TBK1 have been identified and used as genetic adjuvants to enhance DNA vaccine immunogenicity in mouse models. However, the mechanisms that induce innate immune responses by DNA vaccines are still unclear. In this review, we will discuss innate immune signaling upon DNA vaccination and genetic adjuvants of innate immune signaling molecules.
Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation, 7-6-8 Saito-asagi, Ibaraki, Osaka 567-0085, Japan. kobi@nibio.go.jp.|Laboratory of Vaccine Science, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka 567-0871, Japan. kobi@nibio.go.jp.
Kouji
K
Kobiyama
Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation, 7-6-8 Saito-asagi, Ibaraki, Osaka 567-0085, Japan. n-jonai@nibio.go.jp.|Laboratory of Vaccine Science, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka 567-0871, Japan. n-jonai@nibio.go.jp.
Nao
N
Jounai
Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation, 7-6-8 Saito-asagi, Ibaraki, Osaka 567-0085, Japan. t-aoshi@nibio.go.jp.|Laboratory of Vaccine Science, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka 567-0871, Japan. t-aoshi@nibio.go.jp.
Taiki
T
Aoshi
Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation, 7-6-8 Saito-asagi, Ibaraki, Osaka 567-0085, Japan. tozuka-miyuki@nibio.go.jp.|Laboratory of Vaccine Science, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka 567-0871, Japan. tozuka-miyuki@nibio.go.jp.
Miyuki
M
Tozuka
Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation, 7-6-8 Saito-asagi, Ibaraki, Osaka 567-0085, Japan. takeshita.fumihiko@japanvaccine.co.jp.|Laboratory of Vaccine Science, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka 567-0871, Japan. takeshita.fumihiko@japanvaccine.co.jp.
Fumihiko
F
Takeshita
Laboratory of Malaria Immunology, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka 567-0871, Japan. ccoban@biken.osaka-u.ac.jp.
Cevayir
C
Coban
Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation, 7-6-8 Saito-asagi, Ibaraki, Osaka 567-0085, Japan. kenishii@nibio.go.jp.|Laboratory of Vaccine Science, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka 567-0871, Japan. kenishii@nibio.go.jp.
Ken J
KJ
Ishii
DNA sensor; DNA vaccine; adjuvant; innate immune responses